Skip to Main Content

Anavex Life Sciences, a small drug maker in New York City, has committed publicly to an ambitious roster of clinical trials for its lead pipeline product Anavex 2-73, including trials in Alzheimer’s, Parkinson’s, and other serious neurological diseases.

But does Anavex have clearance from regulators in the U.S. and Europe to enroll patients in those Anavex trials?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.